AzTrials
AzTrials

Adenocarcinoma of the StomachPhase 2NCT05715931

Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

A Phase 2 study testing Toripalimab, Trastuzumab and 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT) in people with Adenocarcinoma of the Stomach and Adenocarcinoma of Esophagogastric Junction, run by Yu jiren at 8 sites in China.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This study is a prospective, single arm, multi-center phase II clinical trial designed to evaluate the efficacy and safety of perioperative chemotherapy with FLOT regimen and trastuzumab in combination with toripalimab in participants with resectable HER2 positive locally advanced gastric or esophagogastric junction… Read more about this study

Who is it for?
Ages 18 to 80 years
What is being tested?
Toripalimab, Trastuzumab and 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT)
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
8 sitesChina
Study dates
30 May 2023to 1 Oct 2028
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Voluntary participation in the clinical study; fully understands and is informed of the study and has signed the Informed Consent Form (ICF).
  • The gender is not limited. Age: ≥ 18 years and ≤ 80 years old.
  • Gastric or esophagogastric junction adenocarcinoma confirmed by pathology.
  • HER2-positive status defined as either IHC score of 3+ or IHC 2+ with amplification proven by fluorescent in situ hybridization (FISH) based on pretreatment endoscopic biopsies.
  • Clinical stage at presentation: cT2-T4b, N+/-, M0 as determined by AJCC staging system, 8th edition.
  • The definition of metastatic lymph nodes: a lymph node must be ≥ 10mm in short axis when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm) according to the guideline of Response Evaluation Criteria in Solid Tumours (RECIST version 1.1)
Show all 28Show fewer
  • Participants with a performance status of 0 ~ 1 on the Eastern Cooperative Oncology Group (ECOG) within 7 days before the first dose of study treatment.
  • Life expectancy ≥ 6 months.
  • Agreement of providing pretreatment endoscopic biopsies specimens and surgical specimens for biomarker analysis, as well as the peripheral blood, feces and urine sample.
  • The functions of the vital organs meet requirements as follow (within 14 days before the first dose of study treatment, participant has not received treatment of recombinant human thrombopoietin or granulocyte stimulating factor):
  • Hematological function：
  • White blood cell count (WBC): 3.5 × 10 ^ 9 / L ~12.0 × 10 ^ 9 / L；
  • Absolute neutrophil count (ANC) ≥ 1.5 × 10 ^ 9 / L；
  • Platelet count (PLT) ≥ 100 × 10 ^ 9 / L；
  • Hemoglobin (Hb) ≥ 90 g / L.
  • Hepatic function：
  • Total bilirubin (TBIL) ≤ 1.5 × ULN (upper limit of normal);
  • Aspartate aminotransferase (AST) ≤ 2.5 × ULN;
  • Alanine aminotransferase (ALT) ≤ 2.5 × ULN;
  • Albumin (ALB) ≥ 30 g / L.
  • Renal function：
  • Creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance ≥ 60 ml / min for those with creatinine level > 1.5 × ULN.
  • Coagulation function：
  • International normalized ratio (INR) ≤ 1.5;
  • Prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
  • Cardiac function:
  • The left ventricular ejection fraction (LVEF) value ≥ 55 %, as assessed by echocardiography
  • Female of childbearing age must meet requirements: urine or serum pregnancy test must be negative within 7 days before the first dose of study treatment, and she must agree to use adequate contraception methods or keep abstinence (starting with the ICF is signed through 120 days after the last dose of toriplimab, or 210 days after the last dose of trastuzumab, or 180 days after the last dose of chemotherapy, whichever is longer, and should not be breastfeeding. For the male participants must meet requirements: agree to use adequate contraception methods or keep abstinence (starting with the ICF is signed through 120 days after the last dose of toriplimab, or 210 days after the last dose of trastuzumab, or 180 days after the last dose of chemotherapy, whichever is longer).

Who cannot join

  • Prior systemic therapy for treatment of gastric cancer (surgery, chemotherapy, radiotherapy, targeted therapy or immunotherapy).
  • Previous or concurrent have other active malignant tumors within the past 5 years (except for basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, prostate cancer or cervical cancer or breast cancer in situ that has undergone curative therapy).
  • Participants with gastric outlet obstruction, or unable for oral take, or severe gastrointestinal bleeding.
  • Myocardial infarction within 6 months before the first dose of study treatment, uncontrolled angina, arrhythmia which need medical intervention (including but not limited to cardiac pacemaker), congestive heart failure (New York Heart Association (NYHA) class III or IV).
  • Existence of chronic diarrhea (watery diarrhea: ≥ 5 times per day).
  • Participants with active infection within 14 days before the first dose of study treatment which need medical intervention.
Show all 16Show fewer
  • Participants with active tuberculosis.
  • Previous or concurrent diagnosed with interstitial lung disease by imaging or symptoms.
  • Any of the following test is positive: Human Immunodeficiency Virus (HIV) antibody, Hepatitis B surface Antigen (HBsAg), or Hepatitis C Virus (HCV) antibody.
  • Participants who need long-term systemic steroid therapy (> 10 mg/d prednisone equivalent) or any other form of immunosuppressive therapy within 14 days before the first dose of study treatment or during the study period.
  • Concurrent or previous have severe allergic reaction to any antibody-based drugs.
  • Existence of any concurrent autoimmune disease, excepting participants with diabetes mellitus type I, hypothyroidism requiring only hormone replacement therapy.
  • Receive live vaccines within 28 days before the first dose of study treatment or during the study period, excepting inactivated viral vaccines for seasonal influenza.
  • Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
  • Existence of systemic disease that is difficult to control despite treatment with several agents, for example, diabetes mellitus, hypertension, etc.
  • Existence of other serious physical or mental diseases or serious laboratory abnormalities that may increase the risk of participating in the study. Participants who were judged unsuitable as subjects of this trial by investigator.

Trial locations and contacts

8 sites in 1 country.

8 sites in 1 country

China8 sites

  • The First Affiliated Hospital, College of Medicine, Zhejiang University

    Hangzhou, Zhejiang, 310003

  • The Second Affiliated Hospital, College of Medicine, Zhejiang University

    Hangzhou, Zhejiang, 310003

  • Huzhou Central Hospital

    Huzhou, Zhejiang, 313099

  • Lishui Central Hospital

    Lishui, Zhejiang, 323000

  • Ningbo First Hospital

    Ningbo, Zhejiang, 315010

  • Ningbo Medical Center LiHuiLi Hospital

    Ningbo, Zhejiang, 315048

  • Ningbo Second Hospital

    Ningbo, Zhejiang, 315099

  • Taizhou Hospital

    Taizhou, Zhejiang, 317099

Other trials in China

About this study

Official title: A Multi-center, Phase II Study to Evaluate Efficacy and Safety of Perioperative Chemotherapy With Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel (FLOT) and Trastuzumab in Combination With Toripalimab in Patients With HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

This study is a prospective, single arm, multi-center phase II clinical trial designed to evaluate the efficacy and safety of perioperative chemotherapy with FLOT regimen and trastuzumab in combination with toripalimab in participants with resectable HER2 positive locally advanced gastric or esophagogastric junction adenocarcinoma.

Being tested
Toripalimab, Trastuzumab, 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT)
Keywords
Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma, Perioperative Chemotherapy, Trastuzumab, Toripalimab

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ToripalimabDrug

    Toripalimab, 240 mg IV infusion on Day 1 of each 21 day cycle for 3 cycles prior to surgery and 3 cycles after surgery.

  • TrastuzumabDrug

    Trastuzumab, 8 mg/kg IV loading dose at 1st administration and then 6 mg/kg IV on Day 1 of each 21 day cycle for 3 cycles before surgery and 3 cycles after surgery. The first administration of trastuzumab after surgery should also be given at the loading dose of 8 mg/kg.

  • 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT)Drug

    Pre-operative treatment 4 cycles and post-operative treatment 4 cycles:

    Docetaxel 50 mg/m², IV on day 1 of each 14 day cycle; Oxaliplatin 85 mg/m² , IV on day 1 of each 14 day cycle; Leucovorin 200 mg/m² or Levoleucovorin 100 mg/m², IV on day 1 of each 14 day cycle; 5-FU 2600 mg/m², IV over 24 h on day 1 of each 14 day cycle.

Study groups in NCT05715931
Study groupRoleWhat they receive
Toripalimab plus Trastuzumab with FLOT(5-FU+leucovorin+docetaxel+oxaliplatin)ExperimentalNot described
Receives: Drug: Toripalimab; Drug: Trastuzumab; Drug: 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rate of pathological complete responses (pCR)

    Percentage of patients with pCR referring to the total number of enrolled and eligible patients, as evaluated centrally by a reference pathologist.

    Measured: From enrollment to surgery after pre-operative treatment (up to approximately 24 months)

Secondary outcomes (3)

  1. Overall survival

    The duration of overall survival (OS) will be determined by measuring the time interval from enrollment to the end of follow up or death from any cause

    Measured: From enrollment to the end of follow up or death from any cause (up to approximately 60 months)

  2. Progression-free survival

    Progression-free survival (PFS) will be defined as the time from enrollment to the end of follow up or the time of disease progression or relapse or death from any cause

    Measured: From enrollment to the end of follow up or the time of disease progression or relapse or death from any cause (up to approximately 60 months)

  3. The incidences and types of adverse events (AE) and severe adverse events (SAE)

    The incidences and types of adverse events that occur during treatment will be evaluated according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.3

    Measured: From enrollment to 90-day after the last dose administration (up to approximately 27 months)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Feb 2023
  2. Study start30 May 2023
  3. Primary completion10 Feb 2026
  4. Study completion1 Oct 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Drug: 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT) Drug: Trastuzumab Drug: Toripalimab
Masking
None (open label)
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05715931
Sponsor's protocol ID
IIT20220076C-R1
Status last verified
Sep 2026
First submitted
28 Jan 2023
Last updated
9 Sep 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Toripalimab, Trastuzumab and 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT) in people with Adenocarcinoma of the Stomach and Adenocarcinoma of Esophagogastric Junction, run by Yu jiren at 8 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 28 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 9 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 8 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rate of pathological complete responses (pCR) (time frame: From enrollment to surgery after pre-operative treatment (up to approximately 24 months)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05715931.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in